International Journal of Medical Science and Clinical Research Studies

Examining the Relationship between Quality of Life and Baseline Hemoglobin Level in Lung Cancer with Chemotherapy Treatment Using EORTC QLQ-LC13

Wed, 01 May 2024 00:00:00 +0000

Background: The effect of lung cancer and its various treatments on the overall well-being can be substantial. This study seeks to examine the correlation between quality of life and baseline hemoglobin (Hb) levels in lung cancer patients who are receiving chemotherapy.

Method: This study involved 30 patients with non-small cell lung cancer (NSCLC) who underwent platinum-based chemotherapy. Baseline Hb level were collected from medical records. The patients' quality of life was assessed using interviews utilizing the EORTC QLQ-LC13 questionnaire.

Result: Baseline Hb levels and pain relief after medication score was positively correlated (r=0.559, p=0.001). Baseline Hb levels and difficulty swallowing score was negatively correlated (r=-0.386, p=0.035). Determined cut-off point for the total score was 303.5. However, the correlation between Hb levels and overall quality of life was insignificant (r=-0.096, p=0.615).

Conclusion: According to the quality of life indicators in the questionnaire, there is a notable association between lower baseline Hb levels and reduced effectiveness of pain relief medication, as well as an increase in difficulty swallowing. However, the underlying cause for this correlation is unclear. On the other hand, the correlation between baseline Hb levels and the overall scores of quality of life in the questionnaire was not found to be significant.

Pharmacological and Nonpharmacological Interventions for Prevention and Management of Pulmonary Embolism in Patients with Cardiac Comorbidities: A Literature Review

Fri, 03 May 2024 00:00:00 +0000

Pulmonary embolism (PE) presents significant healthcare challenges and potentially life-threatening consequences, demanding a nuanced approach to management. This systematic review aimed to critically evaluate available pharmacological and nonpharmacological interventions for PE, analyzing their efficacy and safety in patients with cardiac comorbiditie, ranging from traditional anticoagulants like warfarin to novel direct oral anticoagulants (DOACs) or thrombolytic therapies is commercially available options with varying benefits and limitations. Nonpharmacological interventions, including catheter-directed therapies and embolectomy, provide alternative avenues, especially when thrombolysis is contraindicated despite advancements, and gaps persist, particularly in reconciling efficacy with safety profiles and optimizing resource allocation. Addressing these challenges necessitates a multidisciplinary approach, integrating clinical expertise with evidence-based practices. By exploring these interventions' intricacies and implications, this review aims to inform clinicians, researchers, and policymakers, fostering improved care pathways and better outcomes for patients facing the complex landscape of PE management.

Scalp Spinal Cell Carcinoma Managed with Resection and Ying Yang Flap

Sat, 04 May 2024 00:00:00 +0000

The second most frequent type of non-melanoma skin cancer is cutaneous squamous cell carcinoma (cSCC). We present the case of a squamous cell carcinoma of the scalp with surgical management and the importance of the Ying-yang flap. Ying-Yang flaps" are employed when there is stress on the incision, especially on the scalp and lower extremities.

Acute Infarct of Myocardium without Coronary Arterial Obstructive Disease in a Patient with Colon Cancer: A Case Report

Sat, 04 May 2024 00:00:00 +0000

We report a 40-year-old female with colon cancer, in its first session of treatment with capecitabine/oxaliplatin, who presented an event of acute coronary syndrome type myocardial acute infarction with ST inferior elevation in the first 30 days after initiation of adjuvant treatment, angiographically without lesions and echocardiographically presented impaired ventricular function. This case report illustrates myocardial damage induced by antimetabolites in an acute manner.